MétaCan
Menu
Back to cohort

Abstract B24: Genomic prediction of response to PARP inhibition in breast cancer

2017· article· en· W2604158559 on OpenAlexaffabout
Saima Hassan, Amanda Esch, Laura M. Heiser, Joe W. Gray

Bibliographic record

VenueMolecular Cancer Research · 2017
Typearticle
Languageen
FieldMedicine
TopicPARP inhibition in cancer therapy
Canadian institutionsFluidigm (Canada)Université de Montréal
Fundersnot available
KeywordsOlaparibVeliparibPARP inhibitorCancer researchBreast cancerTriple-negative breast cancerCarboplatinCancerBiologyMedicinePoly ADP ribose polymeraseOncologyInternal medicineGeneChemotherapyGeneticsCisplatin

Abstract

fetched live from OpenAlex

Abstract Efficacy of PARP inhibition has been demonstrated in several cancer types including prostate, ovarian, and breast. Most recently, anti-PARP therapy was shown to be effective in combination with carboplatin in triple-negative breast cancer patients in the neoadjuvant setting. However, it is not yet well known which subset of triple-negative breast cancers will benefit from single-agent anti-PARP therapy. We determined the therapeutic efficacy of three PARP inhibitors: veliparib, olaparib, and BMN 673, in a panel of eight triple-negative breast cancer cell lines. We used a 10-day in-vitro assay, after which we fixed the cells and determined 53BP1 expression using immunofluorescence and high-content imaging. We used cell counts to derive IC50 values and enumerated 53BP1 foci per cell to determine EC50 values. We used pre-treatment whole-transcriptome data to identify genes associated with 53BP1 response using gene set enrichment and pathway enrichment analysis. We determined the prevalence of these genes in a dataset of triple-negative breast cancer patients, and performed survival analysis. We found PARP inhibition to be effective in both BRCA-mutant and BRCA wild-type breast cancer cell lines. BMN 673 was the most potent PARP inhibitor, with the lowest concentrations required for DNA damage (measured by 53BP1 expression) and cell kill (measured by cell count), followed by olaparib, and then veliparib. We found a strong correlation between the IC50 values for cell count and the EC50 values for 53BP1 response. We identified a gene set associated with 53BP1 response, which was involved with three major pathways: DNA repair, cell cycle, and programmed cell death. These genes were found to be downregulated in triple-negative breast cancer patients. Patients with aberrations in these genes demonstrated poorer overall survival (P = 0.03). In conclusion, we identified a gene set involved with DNA repair, cell-cycle, and programmed cell death, which was associated with poor outcomes in triple-negative breast cancer patients that could potentially benefit from anti-PARP therapy. Citation Format: Saima Hassan, Amanda Esch, Laura M. Heiser, Joe W. Gray. Genomic prediction of response to PARP inhibition in breast cancer [abstract]. In: Proceedings of the AACR Special Conference on DNA Repair: Tumor Development and Therapeutic Response; 2016 Nov 2-5; Montreal, QC, Canada. Philadelphia (PA): AACR; Mol Cancer Res 2017;15(4_Suppl):Abstract nr B24.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.633
Threshold uncertainty score0.862

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0020.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0010.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.085
GPT teacher head0.439
Teacher spread0.354 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2017
Admission routes2
Has abstractyes

Explore more

Same venueMolecular Cancer ResearchSame topicPARP inhibition in cancer therapyFrench-language works237,207